In malaria-endemic countries, G6PD testing at the 30% threshold can now be achieved using point-of-care qualitative and quantitative rapid diagnostic tests,30, 31 which could allow for the widespread delivery of a safe and effective short-course primaquine regimen. This evidence concerns the gene G6PD and malaria.